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Background: Phenotyping asthma according to airway inflammation allows identification of responders to targeted
therapy. Induced sputum is technically demanding. We aimed to identify predictors of sputum inflammatory
phenotypes according to easily available clinical characteristics.
Methods: This retrospective study was conducted in 508 asthmatics with successful sputum induction recruited
from the University Asthma Clinic of Liege. Receiver-operating characteristic (ROC) curve and multiple logistic
regression analysis were used to assess the relationship between sputum eosinophil or neutrophil count and a set
of covariates. Equations predicting sputum eosinophils and neutrophils were then validated in an independent
group of asthmatics.
Results: Eosinophilic (≥3%) and neutrophilic (≥76%) airway inflammation were observed in 46% and 18% of
patients respectively. Predictors of sputum eosinophilia ≥3% were high blood eosinophils, FENO and IgE level and
low FEV1/FVC. The derived equation was validated with a Cohen’s kappa coefficient of 0.59 (p < 0.0001). ROC curves
showed a cut-off value of 220/mm3 (AUC = 0.79, p < 0.0001) or 3% (AUC = 0.81, p < 0.0001) for blood eosinophils to
identify sputum eosinophilia ≥3%. Independent predictors of sputum neutrophilia were advanced age and high
FRC but not blood neutrophil count.
Conclusion: Eosinophilic and paucigranulocytic asthma are the dominant inflammatory phenotypes. Blood
eosinophils provide a practical alternative to predict sputum eosinophilia but sputum neutrophil count is poorly
related to blood neutrophils.
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Asthma is a heterogeneous disease of the airways. The
traditional guidelines for asthma diagnosis include suggest-
ive clinical symptoms and the demonstration of airflow
variability. However, symptoms and lung function are
insensitive in reflecting the underlying airway inflammation.
There is increasing evidence that phenotyping asthma
according to airway inflammation can allow the identification
of subgroups of patients who are more likely to respond to
targeted therapy. In particular, important studies have
confirmed that eosinophilic airway inflammation most* Correspondence: fschleich@chu.ulg.ac.be
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reproduction in any medium, provided the orreliably predicts the response to anti-inflammatory treatment
such as inhaled corticosteroid [1,2] and anti-IL5 [3,4]. Recent
studies have demonstrated the usefulness of induced sputum
to guide asthma treatment [5,6]. These studies showed that
normalizing airway eosinophilic inflammation allowed better
control of asthma with reduced exacerbations and hospital
admissions. There is however no evidence that inhaled
corticosteroids may improve short term asthma control in
the absence of uncontrolled eosinophilic inflammation as
encountered in pauci-granulocytic asthma [7]. On the other
hand data suggest that neutrophilic asthma could be best
targeted by using clarithromycin [8]. Characterising the
inflammatory phenotype in patients with chronic respiratory
symptoms can thus be more important than giving an
“asthma” label to predict response to anti-inflammatoryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic, functional and inflammatory
characteristics for the whole population
Characteristics
N. 508
Sex (M/F) 201/307
Age, yrs 52 (19–88)
Height, cm 167 ± 9
Weight, kg 74 ± 16
Atopy (Y/N) 296/212 (58%)
Current Smoker (n) (pack-yr) 101 (22 (0.5-60) pack-yr)
Ex-smokers (n) (pack-yr) 99 (15 (0.5-90) pack-yr)
FEV1,% predicted 84 ± 19
Sputum eosinophils,% 2 (0–94)
Sputum neutrophils,% 45 (0–100)
ICS therapy
Steroid naïve 153 (30%)
Low dose ICS 73 (15%)
Moderate dose ICS 138 (27%)
High dose ICS 144 (28%)
Data are presented as mean ± SD or median (range). FEV1, forced expiratory
volume in 1 s. ICS: inhaled corticosteroids. Low dose: ≤500 μg/day
beclomethasone; Moderate dose: 500-1000 μg/day beclomethasone; High
dose: >1000 μg/day beclomethasone.
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non-invasive collection of airway cells is considered as the
gold standard to identify inflammatory asthma phenotype. It
is however technically demanding and time consuming.
Exhaled nitric oxide (FENO) has already been identified [9,10]
as a valid marker of airway eosinophilic inflammation. We
currently however lack of marker predicting airway
neutrophilic inflammation. It is unclear whether systemic
inflammation is able to predict inflammatory phenotypes
either eosinophilic or neutrophilic. This alternative test is
biologically plausible since the infiltrating granulocytes in
the airway are bone marrow-derived cells which access the
airway through the circulation. The appeal of the approach
comes from the ease of sample collection of peripheral blood
from subjects of all ages and clinical characteristics.
The purpose of this study was twofold. In a large
asthmatic population encompassing the all disease severity
spectrum, we first sought to assess the proportion of
asthmatic patients displaying eosinophilic vs neutrophilic
vs paucigranulocytic phenotypes based on sputum cell
analysis. Secondly we aimed at determining factors
associated with eosinophilic and neutrophilic phenotypes.
Methods
Subject characteristics and study design
We conducted a retrospective study on a series of 508
patients with asthma recruited from the University
Asthma Clinic of Liege between 1 October 2005 and 27
June 2011 and who had a successful sputum induction.
Their demographic and functional characteristics are
summarised in Table 1. Patients underwent FENO
measurement at a flow rate of 50 ml/s according to the
ERS/ATS recommendations (NIOX, Aerocrine, Sweden).
FENO was first measured and followed by spirometry with
bronchodilation, sputum induction and blood sampling.
All tests were performed on the same day. Asthma was
diagnosed based on the presence of chronic respiratory
symptoms such as cough, breathlessness or dyspnoea
together with the demonstration of airflow variability. The
latter was defined by airway hyper-responsiveness shown
by one or more of the following: increase in Forced
expiratory volume in 1 s (FEV1) of >12% and 200 ml
following inhalation of 400 μg salbutamol or inhaled
concentration of methacholine provoking a 20% fall in
FEV1 of <16 mg/ml. Methacholine challenge was
performed according to a standardised methodology as
previously described [11]. Subjects were characterised as
atopic if they had at least one positive specific IgE
(>0.35 kU/l; Phadia) for at least one common aeroallergen
(cat, dog, house dust mites, grass pollen, tree pollen and a
mixture of moulds). Quality of life was assessed using the
self-administered Asthma Quality of Life Questionnaire
(AQLQ) [12] and asthma control by the Juniper Asthma
Control Questionnaire (ACQ) [13]. Sputum was inducedand processed as previously reported [14] and was
successful in 78% of the patients encountered in our
asthma clinic (data not shown). Cell count were estimated
on samples centrifuged (Cytospin) and stained with Diff
Quick after counting 500 cells (Dade, Brussels, Belgium).
Eosinophilic phenotype was defined as ≥3% sputum
eosinophil count while neutrophilic phenotype consisted
of ≥76% sputum neutrophil counts [15]. When deriving
the upper limit of the 90% reference interval, abnormally
high neutrophil count ranges from 49% according to
Spanevello [16] to 93% according to Thomas [17], most
of the authors setting the threshold between 61% and
76%. We defined an abnormally high sputum neutrophil
count as a percentage ≥76% (>mean + 1.7SD of our
reference value found in healthy subjects matched for age
(34.9+/-24.3%; n = 113)) [15].
Statistical analyses
The results were expressed as mean ± SD for continuous
variables; median and interquartile ranges (IQR) were
preferred for skewed distributions. For categorical
variables, the number of observations and percentages
were given in each category. Comparisons between
different subgroups were performed with a Kruskal-
Wallis test. The Spearman correlation coefficient was
used to measure the association between clinical
parameters. The receiver-operating characteristic (ROC)
curve was constructed to determine the concentration of
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sputum eosinophil count ≥3% or a sputum neutrophil
count ≥76% respectively. Logistic regression analysis
was used to assess the relationship between the binary
outcome (sputum eosinophil count ≥3% or sputum
neutrophil count ≥76%) and a set of covariates,
individually or in combination (gender, age, height,
weight, atopy, smoking status, IgE, blood eosinophil and
neutrophil count, FEV1%, FEV1/FVC, TLC, FRC, KCO,
PC20M, Reversibility, Fibrinogen, CRP, FENO, ACQ,
AQLQ, ICS therapy). The results were considered to be
significant at the 5% critical level (p < 0.05). The ability
of the equation to predict sputum eosinophilia or
neutrophilia was tested in an independent population of
178 asthmatics recruited between July 2011 and May
2012. The demographic, functional and inflammatory
characteristics of the validation population were similar
to those of the study population.
As IgE levels were missing in 40 patients, the equation
predicting sputum eosinophilia was validated in 138
patients. The agreement between predicted and observed
value was tested by Cohen Kappa’s coefficient. Calculations
were done using SAS version 9.1 (SAS Institute, Cary,
North Carolina, USA).
This study was conducted with the approval of the
ethics committee of CHU Liege B70720096732,
reference Liege 2009/161.
Results
The demographic and functional characteristic of the
patients are given in Table 1.
Of the 508 subjects who underwent a successful sputum
induction, 211 (42%) had eosinophilic inflammation (≥3%
eosinophils), 80 (16%) neutrophilic inflammation (≥76%
neutrophils), 14 (3%) mixed granulocytic and 203 (40%)
paucigranulocytic (sputum eosinophil count <3% and
sputum neutrophil count <76%) inflammation (Tables 2Table 2 Demographic characteristics according to the inflamm
Paucigranulocytic phenotype Eosinophilic pheno
N. 203 (40%) 211 (41.5%)
Sex (M/F) 72/131 101/110*
Age, yrs 51 (21–86) 51 (19–87)
Atopy (Y/N) 100/103 (49%) 140/71 (66%)*
Smoking (Y/N) 48/155 (23%) 38/173 (18%)
ICS therapy
-Steroid naïve 66 (32.5%) 59 (28%)
-Low dose 31 (15.3%) 37 (17.5%)
-Moderate dose 58 (28.6%) 54 (25.6%)
-High dose 48 (23.6%) 61 (28.9%)
*p < 0.05, **p < 0.001, ***p < 0.0001 *Paucigranulocytic asthma is used as the comp
ICS: inhaled corticosteroids. Low dose: ≤500 μg/day beclomethasone; Moderate dos
>1000 μg/day beclomethasone.and 3, Figure 1). These proportions were rather similar
after exclusion of steroid treated patients (Table 4).
Compared to paucigranulocytic phenotype, eosinophilic,
neutrophilic and mixed granulocytic phenotypes were
characterised by a poorer lung function. Eosinophilic
phenotype exhibited higher frequency of atopy, higher
levels of IgE, higher bronchial hyperresponsiveness to
methacholine, higher FENO levels and lower asthma
control compared to paucigranulocytic. Mixed granulocytic
phenotype had higher levels of fibrinogen, the lowest
lung function and the highest degree of bronchial
hyperresponsiveness to methacholine (Tables 2 and 3).
For the whole group there was a significant positive
relationship between blood eosinophil count, either
expressed as percentage or absolute value, and percentage
of sputum eosinophil count (r = 0.6, p < 0.0001; r = 0.6,
p < 0.0001; respectively; Figure 2). Using the ROC curve
method we found that a blood eosinophil count ≥220/mm3
yielded 77% sensitivity and 70% specificity (Area under the
curve (AUC) = 0.79, p < 0.0001, Figure 3) for identifying a
sputum eosinophil count ≥3% in the whole population. By
constructing ROC curve we found that a cut-off value of
3% for percentage of blood eosinophils was able to identify
the presence of a sputum eosinophil count ≥3% with 75%
sensitivity and 73% specificity (AUC= 0.81, p < 0.0001,
Figure 4). The measure of blood eosinophils was as
efficient as FENO (cut-off = 41 ppb, AUC 0.79, p < 0.0001)
for identification of sputum eosinophilia ≥3%. The
comparison of the AUC for both tests failed to
demonstrate a significant difference (p = 0.77).
We further sought to determine the factors associated
with sputum eosinophilic phenotype using multiple logistic
regression models. When combining all variables into the
model, percentage of blood eosinophils (logit-transformed;
p < 0.0001), FEV1/FVC (p = 0.0021), FENO (log-transformed;
p < 0.0001), and IgE (log-transformed; p = 0.0085) were
independent factors associated with the presence of sputumatory phenotype
type Neutrophilic phenotype Mixed granulocytic phenotype
80 (15.7%) 14 (2.8%)
21/59 7/7
57 (21–84) 68 (31–88)
48/32 (60%) 8/6 (57%)
12/68 (15%) 3/11 (21%)
25 (31.3%) 3 (21.4%)
4 (5%)* 1 (7.2%)
23 (28.7%) 3 (21.4%)
28 (35%) 7 (50%)
arator.
e: 500-1000 μg/day beclomethasone; High dose:
Table 3 Functional and inflammatory characteristics according to the inflammatory phenotype
Paucigranulocytic phenotype Eosinophilic phenotype Neutrophilic phenotype Mixed granulocytic phenotype
IgE, kU/l 84 (1–7338) 211 (3–17183)*** 107 (2–7338) 346 (1–2063)
Blood eosinophils,/mm3 160 (0–1220) 360 (0–3220)*** 170 (20–1020) 420 (190–3040)***
Blood eosinophils,% 2 (0–13) 4.5 (0–26)*** 1.9 (0.2-15) 5 (1.3-30)***
Blood neutrophils,/mm3 4030 (76–11080) 4220 (1820–15410) 5000 (2070–10440) 4245 (3520–6170)
Blood neutrophils,% 59 (27–82) 55 (32–91)* 62 (42–80) 59 (43–68)
FEV1,% predicted 90 ± 17 80 ± 20*** 79 ± 20*** 72 ± 14***
FEV1/FVC,% 77 ± 9 71 ± 10*** 72 ± 11*** 69 ± 9***
TLC,% predicted 99 ± 16 102 ± 18 102 ± 18 101 ± 14
FRC,% predicted 103 ± 27 104 ± 19 119 ± 32 111 ± 22
KCO,% predicted 90 ± 19 92 ± 21 91 ± 19 100 ± 10
PC20, mg/ml 4.42 (0.13-16) 2.02 (0.025-16)** 3.22 (0.05-16) 1.08 (0.53-2.2)**
Reversibility,% 8 ± 9 15 ± 17** 8 ± 10 12 ± 10
Sputum eosinophils,% 0.4 (0–2.9) 18 (3–94) 0.2 (0–2.8) 4.3 (3–8)
Sputum neutrophils,% 41 (0–76) 33 (0–76) 87 (77 – 100) 82 (76–92)
Fibrinogen, g/l 3.1 (2–6.3) 3.1 (2–7.2) 3.3 (1.9-10) 4.1 (2.7-6.3)*
CRP, mg/l 1.6 (0.2-14) 1.8 (0.2-14) 2.3 (0.2-10) 1.9 (1.1-6)
FENO, ppb 16 (1–128) 53 (2–247)*** 22 (0–192) 41 (12–161)*
ACQ 1.82 ± 1.15 2.16 ± 1.36* 2.09 ± 1.88 2.09 ± 1.16
Global AQLQ 4.6 ± 1.3 4.58 ± 1.34 4.76 ± 1.46 4.45 ± 1.74
-Emotion 4.92 ± 1.35 4.57 ± 1.63 4.9 ± 1.76 4.64 ± 1.83
-Symptoms 4.46 ± 1.46 4.42 ± 1.43 4.65 ± 1.54 4.39 ± 1.5
-Activity 4.71 ± 1.36 4.79 ± 1.44 4.84 ± 1.49 4.55 ± 1.80
-Environnement 4.48 ± 1.50 4.55 ± 1.55 4.81 ± 1.67 4.70 ± 2.15
*p < 0.05, **p < 0.001, ***p < 0.0001 *Paucigranulocytic asthma is used as the comparator.
Data are presented as mean ± SD or median (range); PC20 is expressed as geometric mean (range). ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of
Life Questionnaire; FENO, exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PC20, concentration required to provoke a fall in FEV1 of 20% or more; FVC,
forced vital capacity. CRP, C-Reactive Protein; FRC: Forced residual capacity; KCO: Carbon monoxide transfer coefficient; TLC: total lung capacity. Paucigranulocytic
asthma is used as the comparator.
Figure 1 Proportion of various inflammatory phenotypes
according to cellularity of induced sputum in a large cohort
of asthmatics.
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we established a formula to predict the presence of a
sputum eosinophil count ≥3%:
ln π= 1−πð Þð Þ ¼ L ¼ 2:92þ 1:218
ln Blood eos%ð Þ= 100−Blood eos%ð Þð Þ
þ0:217 ln IgEð Þ−0:039
 FEV1=FVC%ð Þ þ 0:844 ln FENOð Þ
π: probability of sputum eosinophil count ≥ 3%.
Blood eos%: Blood eosinophil count in %.
To test the ability of the equation to predict sputum
eosinophilia, we recruited a validation population of 138
asthmatics that underwent FENO50, spirometry, sputum
induction and gave a blood sample. The agreement
between predicted and observed value of sputum eosino-
phil counts gave a Cohen Kappa’s coefficient of 0.59
(p < 0.0001, lower limit of confidence interval = 0.43).
The specificity and sensitivity were 62.7% and 93.7%respectively while the PPV was 67% and the NPV was
93%.
As far as the sputum neutrophilic phenotype is
concerned, there was a weak correlation between sputum
and blood neutrophil count taken in percentage (r = 0.19,
Table 4 Proportion of asthma inflammatory phenotypes in steroid naïve and steroid-treated patients
Paucigranulocytic phenotype Eosinophilic phenotype Neutrophilic phenotype Mixed granulocytic phenotype
Steroid naïve (n = 153) 65 (42.5%) 60 (39.2%) 25 (16.3%) 3 (2%)
Steroid-treated (n = 355) 138 (38%) 151 (43%) 55 (15%) 11 (3%)*
*p < 0.05.
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Using the ROC curve method, we found a cut-off of 4960/
mm3 and 66% respectively giving a sensitivity of 49% and
37%, a specificity of 70% and 90%, p = 0.03 and p = 0.003,
AUC = 0.59 and AUC = 0.63 respectively.
However, when combining all variables into the logistic
model, age (p = 0.006) and Functional residual capacity
(FRC, p = 0.001) were independent factors associated with
sputum neutrophilia while blood neutrophils were not
significant in this case. The formula to predict the pres-
ence of a sputum neutrophil count ≥ 76% was:
ln
π
1−π
 
¼ L ¼ −5:32þ 0:032 ageþ 0:022 FRC
π: probability of sputum neutrophil count ≥ 76%.
To test the ability of the equation to predict sputum
neutrophilia, we recruited a validation population of
178 asthmatics that underwent spirometry and sputum
induction. The agreement between predicted and
observed value of sputum neutrophil counts gave a
Cohen Kappa’s coefficient of 0.24 (p < 0.0001, lower
limit of confidence interval = 0.12). The specificity and
sensitivity were 21% and 97% respectively. Patients re-
ceiving moderate to high dose ICS had higher sputum
neutrophil count (47.3%) than patients receiving low
dose ICS (38.8%, p = 0.017). Smokers did not have sig-
nificantly higher proportion of neutrophils in theirFigure 2 Relationship between sputum eosinophil count and
blood eosinophil count in a cohort of unselected patients with
asthma (n = 508) by Spearman correlation. There is a significant
correlation between these two parameters (p < 0.0001, Rs = 0.6). AV:
absolute value of blood eosinophils (/mm3).sputum (Median 48.9%) than ex-smokers (Median
50.6%, p = 0.68) or never smokers (Median 44%, p =
0.19). However, neither smoking status nor the dose of
inhaled corticosteroids was able to predict elevated
sputum neutrophil count.Discussion
In a large cohort of asthmatics encompassing all disease
severity spectrum, eosinophilic and pauci-granulocytic
were the most frequent phenotypes while neutrophilic
asthma represented less than one fifth of the inflammatory
patterns. Independent predictors of sputum eosinophil
count ≥3% were the percentage of blood eosinophils, low
FEV1/FVC, high FENO and IgE levels. A cut-off value
of 220/mm3 or 3% for blood eosinophils performed
equally to FENO50 to identify the presence of a sputum
eosinophil count ≥3%. Independent predictors of sputum
neutrophilia were advanced age and high FRC while blood
neutrophil count was not.
The proportion of asthmatics with raised sputum
eosinophil counts was 46% in our series. Gibson et al.
found that 41% of non-smoking asthmatics had a sputum
eosinophil counts >2.5% [18]. The proportion ofFigure 3 Receiver-operating characteristic (ROC) curve for the
whole group to determine the blood eosinophil count value
that best identified a sputum eosinophilia ≥3%. The optimum
cut-off point was 220/mm3 (Sensitivity 77%, specificity: 70%, AUC:
0.790, p < 0.0001).
Figure 4 Receiver-operating characteristic (ROC) curve to
determine the blood eosinophil count percentage that best
identified a sputum eosinophilia ≥3%. The optimum cut-off point
was 3% (Sensitivity: 75%, specificity: 73.4%, AUC: 0.81, p < 0.0001).
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was higher but the thresholds used in those studies were 2
and 1.9% respectively. Our results are similar to the study
of Simpson conducted on 93 subjects using thresholds of
1 and 61% for eosinophilic and neutrophilic inflammation
respectively. This group found 41% eosinophilic asthma,
20% neutrophilic asthma, 31% paucigranulocytic asthma
and 8% mixed granulocytic asthma [19]. The highest
thresholds used in our study certainly explain the lower
proportion of mixed granulocytic and neutrophilic asthma
and the higher proportion of paucigranulocytic asthma in
our patients. A very recent American multicentre study
from McGrath et al. showed that paucigranulocytic
asthma was the dominant phenotype accounting for more
than 50% of patients while eosinophilic asthma (sputum
eosinophil count ≥2%) represented roughly 25%. As in our
study, the neutrophilic phenotype (sputum neutrophil
count > 61%) was quite rare representing less than 15% of
the patients while the mixed granulocytic phenotype was
less than 5% [20].Table 5 Independent predictors of sputum eosinophilia
Parameter β SE p-value
Logit Blood eosinophils,% 1.218 0.19 P < 0.0001
Ln IgE 0.217 0.08 P = 0.0085
FEV1/FVC,% −0.039 0.01 P = 0.0021
FENO 0.844 0.16 P < 0.0001
Ln, Natural logarithm; FEV1, Forced expiratory volume in 1 s; FVC: Forced vital
capacity; FENO, exhaled nitric oxide; SE: standard error.Lung function was less altered in those patients with
paucigranulocytic phenotype while eosinophilic phenotype
exhibited higher FENO levels, higher proportion of males
and atopic patients, higher bronchial hyperresponsiveness
and lower asthma control. Those results are in accordance
with previous studies [11,21-24]. Like Hastie et al. [25], we
identified patients with mixed granulocytic sputum
inflammation exhibiting the lowest lung function. Moreover,
the mixed granulocytic phenotype had higher serum
fibrinogen values pointing to systemic inflammation in this
subgroup. This interesting finding has not been reported so
far in asthma but raised fibrinogen levels have been
demonstrated to be associated with reduced FEV1 and
increased risk of Chronic Obstructive Pulmonary Disease
(COPD) in a population study [26]. As for neutrophilic
asthma there was no special characteristic that distinguishes
this group from the other inflammatory patterns. In particu-
lar neutrophilic asthmatics did not display higher serum C-
Reactive Protein and fibrinogen levels.
Among the factors shown to contribute to airway
eosinophilia, blood eosinophils came first when
performing a multiple logistic regression. There are few
studies assessing the ability of blood eosinophils to
identify airway eosinophilic inflammation. Previous
studies showed that peripheral blood eosinophil count
was correlated with bronchoalveolar lavage eosinophil
count [27] and sputum eosinophil count [28-30]. These
studies have, however, investigated a limited number of
asthmatics and did not provide any threshold value of
blood eosinophils as marker of airway eosinophilia. The
recent American multicentre study found a threshold
value of 220/mm3 as the best compromise for predicting
sputum eosinophil count ≥2% [20]. Another recent study
conducted in COPD showed that a cutoff of 2% peripheral
blood eosinophils had a sensitivity of 90% and specificity
of 60% for identifying a sputum eosinophilia of greater
than 3% at exacerbation. In our study, we confirmed the
correlation between blood and sputum eosinophilic
inflammation in a large cohort of patients. We found
the best threshold being 220/mm3 and 3% and these
thresholds being as effective as FENO at predicting
uncontrolled airway eosinophilic inflammation. Our
findings are in keeping with those recently reported by
McGrath et al. [20]. Compared to blood eosinophils, FENO
has however the advantage of giving immediate results
and its measurement is more comfortable to the patient.
In this study the performance (threshold, sensitivity,
specificity) of FENO to identify sputum eosinophil count is
very similar to the one we reported previously [10]. The
fact that FENO and blood eosinophil counts came out as
independent predictors of sputum eosinophilia in the
multiple logistic regression suggests that these two
markers reflect different mechanisms promoting the
recruitment of eosinophils into the airways.
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prominent sputum eosinophilia are FEV1/FVC and total
serum IgE level. Previous studies have shown that FEV1/
FVC, an index of airway narrowing, was correlated to
sputum eosinophilia [31] and eosinophilic asthma has
been recognized to be frequently associated with atopic
disease [1,7]. In our study, total serum IgE levels were
however best predictor of sputum eosinophilia than atopy
per se, in line with a recent study [20]. From the biological
properties of IgE it can be speculated that high tissue IgE
may prime local mast cells and activate them even without
intervention of allergens [32]. In this view it is interesting
to note that airway mast cell activation demonstrated by
tryptase release is a phenomenon found to be associated
with sputum eosinophils in asthma [33] and COPD [34].
The same approach as for eosinophils was used to predict
the presence of sputum neutrophils. Despite statistically
significant correlation between sputum and percentage
blood neutrophils, the strength of the relationship was
rather poor. As opposed to what we found with eosinophils,
multiple logistic regression analysis demonstrated the
inability of blood neutrophils to predict uncontrolled
sputum neutrophilic inflammation. The accumulation
of airway neutrophils has been reported to be directly
associated with the activation state of circulating
neutrophils in response to the chemokine Interleukin 8
[35,36]. Baines et al. found a correlation between plasma
neutrophil elastase and neutrophilic airway inflammation
[37]. Those data suggest that airway neutrophilic
accumulation could be due to an enhanced neutrophil
activation and migration to the airways independently of
the number of circulating cells. Moreover, it has been
shown that neutrophils can be retained in the pulmonary
microvasculature due to their low deformability, resulting in
a higher concentration than in the systemic circulation. It is
thought that this high concentration of the cells facilitates
their effective recruitment to sites of inflammation [38]. It
seems likely that many could leave the circulation by
chemoattraction, entering the lung without necessarily
having a detectable effect on circulating levels.
From a multiple logistic regression two factors came
out as being independently associated with sputum
neutrophilia. In keeping to what was found by Thomas
et al. in healthy subjects [17] and Woodruff et al. [23] in
asthmatics, age appeared to be a critical factor in our
cohort with sputum neutrophilia rising with age. In
addition to age we also found that FRC was an
independent factor. This suggests that airway neutrophils
may contribute to reduction of inspiratory capacity seen
in some asthmatics. Accordingly, two pediatric studies
reported that percentage neutrophils in bronchoalveolar
lavage directly correlated with air trapping (FRC) in
children with cystic fibrosis [39,40]. However, neither
smoking status nor the dose of inhaled corticosteroidswas able to predict the presence of sputum neutrophil
count.
Conclusion
This study shows that eosinophilic and pauci-granulocytic
are the most frequent asthma phenotypes in a large
unselected asthmatic population. Like FENO, blood
eosinophil counts may provide a practical alternative to
predict sputum eosinophilia ≥3%. In contrast, sputum
neutrophilia is only poorly related to blood neutrophil
count.
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